KEY POINTS
- This retrospective consecutive cohort included 64 patients with 64 symptomatic or recurrent keloids treated between 2014 and 2025. Mean age was 32.7 years, 28.1% of lesions were recurrent, and the most frequent sites were the auricle (40.6%) and presternal region (25.0%).
- Surgical excision was followed by placement of a single interstitial catheter approximately 3–5 mm beneath the skin. Patients also received perilesional triamcinolone, and the first HDR brachytherapy fraction was delivered within six hours of surgery.
- All patients received the same regimen: 12 Gy in three 4-Gy fractions, with at least six hours between fractions. Treatment used CT-based volumetric planning with a 5-mm CTV margin around the catheter, aiming for D90 >95% and V150 <50%; achieved median D90 was 98.5%.
- After a median follow-up of 37.5 months, crude local control was 92.2%, with five recurrences among 64 lesions. Actuarial local control was 95.3% at 12 months and 92.2% at both 24 and 36 months.
- All five recurrences occurred within the first 24 months, after which the local-control curve remained stable. Lesions >5 cm had a numerically higher recurrence rate than smaller lesions (12.5% vs 7.1%), although only eight lesions were >5 cm and no formal subgroup testing was performed.
- No acute toxicity was reported. Late events were limited to mild hypopigmentation in 9.4%, Grade 1 telangiectasia in 6.3%, superficial atrophy in 4.7%, and one case of mild auricular chondritis (1.5%) that resolved conservatively.
- Patient-reported long-term outcomes were also favorable: median POSAS symptom score was 1.0 and appearance score 2.0 on a five-point scale where lower scores are better. Interpretation is limited by the retrospective design, lack of a control arm, only five recurrence events, and inability to isolate the contribution of immediate timing, CT-based planning, fractionation, surgery, or triamcinolone.
CLINICAL TAKEAWAY
For patients requiring postoperative radiotherapy after keloid excision, this series provides a reproducible contemporary HDR brachytherapy template: 12 Gy in three fractions, starting within six hours, with CT-based target coverage. The local-control and toxicity results are strong for a retrospective cohort, but they do not establish superiority over other postoperative radiation techniques or dose schedules.